Older Breast Cancer Patients: Risk for Cognitive Decline

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Georgetown University
Study ID
NCT03451383
Status
Recruiting
Apply to this trial

Conditions

  • Age-related Cognitive Decline
  • Cancer, Breast
  • Cognitive Decline

Eligibility Criteria

Sex
FEMALE
Age
60 Years - 105 Years
Healthy Volunteers
Accepted

Study Details

The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how genetic polymorphisms, inflammatory biomarkers, sleep and physical measures moderate cognitive outcomes. This study is being done nationally, with recruiting sites at Georgetown University, Montgomery General Hospital, Virginia Cancer Specialists, Washington Hospital Center, Reston Breast Care Specialists, Memorial Sloan-Kettering, Moffitt Cancer Center, City of Hope National Medical Center, Hackensack University Medical Center, Indiana University and University of California, Los Angeles.

Key Dates

Start date
Aug 1, 2010
Status verified
Mar 2025
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025

Study Design

Enrollment
1,700 participants (estimated)

Arms

  • Arm: Breast Cancer Case
    Women age 60+ with a newly diagnosed breast adenocarcinoma staged 0-3.
  • Arm: Non-Cancer Controls
    Women age 60+ with no diagnosis of breast cancer.

Primary Outcome Measure

Change in Attention, Processing Speed, Executive Function (APE) Domain [ Time Frame: Baseline and annually up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Georgetown UniversityWashington D.C.District of Columbia20007-

Find similar trials in Washington D.C., DC

By research site
Georgetown University· Washington D.C., DC

Related Studies